137 related articles for article (PubMed ID: 8069194)
21. The labelling index of primitive plasma cells determines the clinical behaviour of patients with myelomatosis.
Joshua D; Petersen A; Brown R; Pope B; Snowdon L; Gibson J
Br J Haematol; 1996 Jul; 94(1):76-81. PubMed ID: 8757512
[TBL] [Abstract][Full Text] [Related]
22. Characterization of a novel interleukin-6 autocrine-dependent human plasma cell line.
Ozaki S; Wolfenbarger D; deBram-Hart M; Kanangat S; Weiss DT; Solomon A
Leukemia; 1994 Dec; 8(12):2207-13. PubMed ID: 7528862
[TBL] [Abstract][Full Text] [Related]
23. Human bone marrow stroma-dependent cell line MOLP-5 derived from a patient in leukaemic phase of multiple myeloma.
Matsuo Y; Drexler HG; Nishizaki C; Harashima A; Fukuda S; Kozuka T; Sezaki T; Orita K
Br J Haematol; 2000 Apr; 109(1):54-63. PubMed ID: 10848782
[TBL] [Abstract][Full Text] [Related]
24. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody.
Stevenson FK; Bell AJ; Cusack R; Hamblin TJ; Slade CJ; Spellerberg MB; Stevenson GT
Blood; 1991 Mar; 77(5):1071-9. PubMed ID: 1995092
[TBL] [Abstract][Full Text] [Related]
25. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
Heider U; Langelotz C; Jakob C; Zavrski I; Fleissner C; Eucker J; Possinger K; Hofbauer LC; Sezer O
Clin Cancer Res; 2003 Apr; 9(4):1436-40. PubMed ID: 12684416
[TBL] [Abstract][Full Text] [Related]
26. Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (araC).
Gati WP; Paterson AR; Belch AR; Chlumecky V; Larratt LM; Mant MJ; Turner AR
Leuk Lymphoma; 1998 Dec; 32(1-2):45-54. PubMed ID: 10037000
[TBL] [Abstract][Full Text] [Related]
27. Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.
Rigolin GM; Tieghi A; Ciccone M; Bragotti LZ; Cavazzini F; Della Porta M; Castagnari B; Carroccia R; Guerra G; Cuneo A; Castoldi G
Br J Haematol; 2003 Mar; 120(6):953-9. PubMed ID: 12648064
[TBL] [Abstract][Full Text] [Related]
28. Flow cytometric studies of nucleoside transport regulation in single chromaffin cells.
Sen RP; Delicado EG; Alvarez A; Brocklebank AM; Wiley JS; Miras-Portugal MT
FEBS Lett; 1998 Feb; 422(3):368-72. PubMed ID: 9498818
[TBL] [Abstract][Full Text] [Related]
29. Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients.
Santonocito AM; Consoli U; Bagnato S; Milone G; Palumbo GA; Di Raimondo F; Stagno F; Guglielmo P; Giustolisi R
Leuk Res; 2004 May; 28(5):469-77. PubMed ID: 15068900
[TBL] [Abstract][Full Text] [Related]
30. The incidence of DNA aneuploidy in multiple myeloma does not correlate with stage of disease.
Nowak R; Oelschlägel U; Range U; Mölle M; Ehninger G
Am J Clin Pathol; 1998 Feb; 109(2):226-32. PubMed ID: 9583896
[TBL] [Abstract][Full Text] [Related]
31. [Detection of myeloma cells in the peripheral blood using flow cytometry].
Adam Z; Klabusay M; Vorlícek J; Hájek R
Vnitr Lek; 1997 Sep; 43(9):592-8. PubMed ID: 9750468
[TBL] [Abstract][Full Text] [Related]
32. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19).
Van Camp B; Durie BG; Spier C; De Waele M; Van Riet I; Vela E; Frutiger Y; Richter L; Grogan TM
Blood; 1990 Jul; 76(2):377-82. PubMed ID: 1695113
[TBL] [Abstract][Full Text] [Related]
33. A new staging system for multiple myeloma based on the number of S-phase plasma cells.
San Miguel JF; García-Sanz R; González M; Moro MJ; Hernández JM; Ortega F; Borrego D; Carnero M; Casanova F; Jiménez R
Blood; 1995 Jan; 85(2):448-55. PubMed ID: 7811998
[TBL] [Abstract][Full Text] [Related]
34. Relation between S-phase fraction of myeloma cells and anemia in patients with multiple myeloma.
Fosså A; Brandhorst D; Myklebust JH; Seeber S; Nowrousian MR
Exp Hematol; 1999 Nov; 27(11):1621-6. PubMed ID: 10560909
[TBL] [Abstract][Full Text] [Related]
35. Plasma cells composing plasmacytoma have phenotypes different from those of myeloma cells.
Sakai A; Fujii T; Noda M; Hyodo H; Oda K; Kimura A
Am J Hematol; 1996 Dec; 53(4):251-3. PubMed ID: 8948665
[TBL] [Abstract][Full Text] [Related]
36. The oncoprotein phenotype of plasma cells from patients with multiple myeloma.
Brown RD; Pope B; Luo XF; Gibson J; Joshua D
Leuk Lymphoma; 1994 Dec; 16(1-2):147-56. PubMed ID: 7696921
[TBL] [Abstract][Full Text] [Related]
37. The clonal hierachy in multiple myeloma.
Rasmussen T; Jensen L; Johnsen HE
Acta Oncol; 2000; 39(7):765-70. PubMed ID: 11145430
[TBL] [Abstract][Full Text] [Related]
38. A prospective study of CD38/45 flow cytometry and immunofluorescence microscopy to detect blood plasma cells in patients with plasma cell proliferative disorders.
Witzig TE; Meyers C; Therneau T; Greipp PR
Leuk Lymphoma; 2000 Jul; 38(3-4):345-50. PubMed ID: 10830741
[TBL] [Abstract][Full Text] [Related]
39. C-kit receptor (CD117) expression on plasma cells in monoclonal gammopathies.
Kraj M; Pogłód R; Kopeć-Szlezak J; Sokołowska U; Woźniak J; Kruk B
Leuk Lymphoma; 2004 Nov; 45(11):2281-9. PubMed ID: 15512818
[TBL] [Abstract][Full Text] [Related]
40. [Myeloma precursor cells].
Iwato K; Kawano MM
Rinsho Ketsueki; 1993 Apr; 34(4):433-8. PubMed ID: 7685432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
